A Phase 3, Open-Label, Single-Arm Study To Assess The Safety Of Hydromorphone Hydrochloride Delivered By Intrathecal Administration
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors CNS Therapeutics; Mallinckrodt Inc.
- 13 Apr 2018 Status changed from active, no longer recruiting to completed.
- 28 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
- 28 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Sep 2017.